Amphastar Pharmaceuticals, Inc 8-K, filed Aug 23, 2021
Amphastar Pharmaceuticals, Inc. (AMPH)
About this 8-K
Amphastar Pharmaceuticals, Inc filed this 8-K on August 23, 2021, reporting on events of August 19, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event Reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of | (Commission File Number) | (IRS Employer Identification |
| |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant's telephone number, including area code: (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered | ||
| | The | ||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b)
On August 19, 2021, David Maris tendered his resignation to the Board of Directors (the “Board”) of Amphastar Pharmaceuticals, Inc. (the “Company”) effective immediately. The resignation of Mr. Maris is not the result of any disagreement with the Company relating to the Company’s operations, policies or practices. Mr. Maris’s service and contributions to the Company are greatly appreciated.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMPHASTAR PHARMACEUTICALS, INC. | ||
Date: August 23, 2021 |
| ||
| By: | /S/WILLIAM J. PETERS |
|
| | William J. Peters | |
| | Chief Financial Officer and Executive Vice President | |
| | ||